13626-60-3

Basic information

• Product Name: 3-HYDROXYISOXAZOLE-5-CARBOXYLIC ACID
• Synonyms: 3-HYDROXYISOXAZOLE-5-CARBOXYLIC ACID;3-oxo-2,3-dihydroisoxazole-5-carboxylic acid(SALTDATA: FREE);5-Isoxazolecarboxylic acid, 2,3-dihydro-3-oxo-;2,3-Dihydro-3-oxo-5-isoxazolecarboxylic acid;3-Hydroxy-5-isoxazolecarboxylic acid
• CAS NO: 13626-60-3
• Molecular Formula: C₄H₃NO₄
• Molecular Weight: 129.07092
• Mol File: 13626-60-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: 265℃
• Appearance: /
• Density: 1.702
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 3-HYDROXYISOXAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXYISOXAZOLE-5-CARBOXYLIC ACID(13626-60-3)
• EPA Substance Registry System: 3-HYDROXYISOXAZOLE-5-CARBOXYLIC ACID(13626-60-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 13626-60-3(Hazardous Substances Data)

Upstream product

• 10068-07-2 methyl 3-hydroxy-5-isoxazolecarboxylate 

Downstream Products

• 1383006-45-8 (2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-[(3-hydroxyisoxazole-5-carbonyl)amino]pentanoic acid ethyl ester trifluoroacetate 
• 1383006-61-8 (2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-[(3-hydroxyisoxazole-5-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]-dioxol-4-ylmethyl ester 
• 1394050-08-8 (2S,4S)-5-Biphenyl-4-yl-4-[(3-hydroxy-isoxazole-5-carbonyl)-amino]-2-hydroxymethyl-5-methyl-hexanoic Acid 
• 1394049-99-0 (2S,4R)-5-biphenyl-4-yl-4-[(3-hydroxyisoxazole-5-carbonyl)amino]-2-hydroxymethyl-2-methylpentanoic acid 
• 1562405-21-3 C₃₂H₃₂ClFN₂O₆ 

Relevant articles and documents

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.